Items where authors include "Collett, C"

Article

Rankin, D, Hart, R, Kimbell, B et al. (18 more authors) (2023) Rollout of closed-loop technology to pregnant women with type 1 diabetes: healthcare professionals' views about potential challenges and solutions. Diabetes Technology and Therapeutics, 25 (4). pp. 1-10. ISSN 1520-9156

Lee, TTM, Collett, C, Man, M-S et al. (23 more authors) (2022) AiDAPT: automated insulin delivery amongst pregnant women with type 1 diabetes: a multicentre randomized controlled trial – study protocol. BMC Pregnancy and Childbirth, 22 (1). 282. ISSN 1471-2393

Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. British Journal of Haematology, 192 (5). bjh.16945. pp. 853-868. ISSN 0007-1048

Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277

Jackson, GH, Davies, FE, Pawlyn, C et al. (20 more authors) (2020) Lenalidomide Before And After ASCT For Transplant-Eligible Patients Of All Ages In The Randomized, Phase III, Myeloma XI Trial. Haematologica. haematol.2020.247130. ISSN 0390-6078

Jackson, GH, Davies, FE, Pawlyn, C et al. (19 more authors) (2019) Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 6 (12). e616-e629. ISSN 2352-3026

Jackson, GH, Davies, FE, Pawlyn, C et al. (19 more authors) (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 20 (1). pp. 57-73. ISSN 1470-2045

Jones, JR, Cairns, DA, Gregory, WM orcid.org/0000-0003-2641-8416 et al. (19 more authors) (2016) Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer Journal, 6 (12). e506. ISSN 2044-5385

Proceedings Paper

Jackson, GH, Davies, FE, Pawlyn, C et al. (18 more authors) (2018) A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San DIego, California, USA. American Society of Hematology , p. 302.